Good News! Olive Bio has been included on the list of Tianjin’s Science and Technology-based SMEs!
Release time:
2024-08-29 14:54
On August 16, 2024, the Tianjin Municipal Science and Technology Bureau officially released the announcement of the “Second Batch of 2024 List of Science and Technology-Based Small and Medium-Sized Enterprises Included in the Database.” In accordance with relevant regulations and evaluation procedures, including the “Evaluation Measures for Science and Technology-Based SMEs” (Guo Ke Fa Zheng [2017] No. 115) and the “Guidelines for Evaluation Services for Science and Technology-Based SMEs” (Guo Ke Huo Zi [2022] No. 67), Tianjin Olive Biotechnology Co., Ltd. was successfully selected based on its strong technological R&D capabilities and innovative strength.
A technology-based small and medium-sized enterprise is one that relies on a certain number of science and technology personnel to engage in scientific research, technological development, and the commercialization of scientific and technological achievements, thereby establishing core, independently owned intellectual property rights. Being included on this list not only reflects the company’s potential for technological innovation but also signifies that the company can look forward to receiving greater policy support and more development opportunities in the future. In the era of technological innovation, Olive Bio has actively responded to national policies, continuously increasing its R&D investment and enhancing its independent innovation capabilities. Through relentless efforts, our company has successfully been listed as a technology-based SME, marking a solid step forward on our journey toward technological innovation.
As a company committed to technological innovation, Olive Bio has consistently embraced bold innovation and steadily moved forward. This inclusion in the database underscores our company’s R&D and innovation capabilities in the fields of nucleosides, nucleotides, and their derivatives. Since our establishment, we have developed several pioneering products that are the first of their kind in China, including: a specialized extension-reaction terminator for nucleic acid mass spectrometry—modified ddNTP (for MALDI-TOF MS); thermally activated dNTPs; a Zika virus replication inhibitor—ddhCTP; and a powerful reagent for high-GC amplification—7-deaza-dGTP. These breakthroughs have filled the gap in the domestic market for high-value-added nucleoside and nucleotide raw materials.
In the future, Olive Bio will steadfastly pursue a path of innovative development, continuously increasing R&D investment and enhancing its technological innovation capabilities. We will actively engage in industry-academia-research collaborations, working closely with universities and research institutions to conduct cutting-edge technology research and tackle key technological challenges, thereby driving continuous improvement in our company’s technological level. Driven by scientific and technological innovation, we will continually optimize our product mix and enhance both the quality and performance of our products. We will proactively expand into both domestic and international markets, strengthen market promotion and brand building, and boost our market share and industry influence. We place great importance on talent development and recruitment, establishing a comprehensive talent incentive system to attract and retain outstanding professionals. We will reinforce our talent pool by cultivating a group of highly qualified individuals endowed with both innovative spirit and practical capabilities, providing solid human resource support for our company’s growth. Taking this opportunity as a springboard, Olive Bio will continue to enhance its innovation capacity, delivering even higher-quality products and services to our customers, and making greater contributions to the advancement of our industry and to national scientific and technological innovation.
Relevant Information
Service hotline:
Company email:
Share
